Cerebral Palsy Market to Eyewitness Robust Expansion at an 8.6% CAGR During the Study Period [2018-2030], States DelveInsight

The Cerebral Palsy emerging therapies such as Xeomin (Incobotulinum toxin A) which is expected to launch in a couple of quarters along with some late launches such as Myobloc (RimabotulinumtoxinB), cumulatively may generate more than USD 500 Million sales in major markets. These emerging treatments will complement the uptake of botulinum toxins which has had very good uptake so far and is expected to see a rise in demand in future too

LAS VEGAS, Jan. 10, 2022 /PRNewswire/ -- DelveInsight's "Cerebral Palsy Market" report provides a thorough comprehension of the Cerebral Palsy historical and forecasted epidemiology and the Cerebral Palsy market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Cerebral Palsy market report also proffers an analysis of the current Cerebral Palsy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Some of the necessary takeaways from the Cerebral Palsy Market Research Report 

• Several key Cerebral Palsy pharmaceutical companies, including Ipsen, Abbvie, Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and others, are developing novel products to improve the Cerebral Palsy treatment outlook. 
• Recent advancements towards Cerebral Palsy treatment and diagnosis, such as screening techniques, have been very successful and resulted in opportunities for developing new drugs.
• The Cerebral Palsy market will increase due to the introduction of Stem Cell Therapies, advances in personalized approaches towards Cerebral Palsy treatment, and ongoing research to focus on the genetic factor of Cerebral Palsy. However, the growth of the Cerebral Palsy market will impede owing to the current treatment mainly relying on off-label therapies, lack of definitive guidelines, and limited pediatric patient enrollment in clinical trials.
• The only two botulinum toxin A for which there are published evidence of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox) and abobotulinum toxin A (Dyport); these toxins are being considered generally safe and appropriate in the treatment for localized upper and lower limb spasticity. Newer Botulinum neurotoxins (BoNTs), such as incobotulinum toxin A (Xeomin) and Myobloc (rimabotulinumtoxin B) are expected to further expand the BoNTs in the Cerebral Palsy market and are expected to position themselves strongly in the Cerebral Palsy treatment paradigm in the coming years.

For further information on Market Impact by Therapies, visit: Cerebral Palsy Drugs Market Analysis 

Cerebral Palsy is a group of disorders that affect movement and muscle tone or posture. 

DelveInsight estimates that the total Cerebral Palsy diagnosed cases in the 7MM were around 1.8 million in 2020. Also, the total Cerebral Palsy prevalent cases of cerebral palsy in the United States were approximately 1 million cases in the same year. 

The Cerebral Palsy Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Cerebral Palsy Prevalent Cases 
• Total Cerebral Palsy Diagnosed Cases 
• Total Cerebral Palsy Type-specific cases
• Cerebral Palsy Treated cases 

Get a complete epidemiological segmentation breakdown @ Cerebral Palsy Epidemiological Analysis 

Cerebral Palsy Treatment Market 

Cerebral Palsy Treatment programs encompass physical and behavioural therapy, pharmacologic and surgical treatments, mechanical aids, and management of associated medical conditions. In physical, occupational, speech, and behavioural therapies, the goals include enhancing patient and caregiver interactions while providing family support. 

Currently, there is no cure for Cerebral Palsy. But pharmacological therapies can help pediatric patients with a lot of muscle pain and stiffness. They can take medicine by mouth or put it under the skin through a pump (the baclofen pump). Surgery can help fix dislocated hips and scoliosis, standard in pediatric patients with cerebral palsy, and leg braces can also help with walking. 

Anticholinergic medications treat uncontrolled movements such as tremors, spasticity, and drooling. Anticonvulsants, which reduce excessive brain stimulation to prevent seizure activity. Antidepressants are often prescribed to those with cerebral palsy to help treat depression, anxiety, and seizures. Muscle relaxants are often the first line of treatment for spasticity in many cases, as the medications are non-invasive and fairly common. Anti-inflammatory medications decrease pain, which can be a significant part of hypoxic-ischemic encephalopathy-related cerebral palsy.

Major Cerebral Palsy therapies currently approved in the 7MM include Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA), among others. At present, some Cerebral Palsy companies have initiated clinical trials that investigate new treatment options. Key players such as Merz Pharmaceuticals (Xeomin), Teva Pharmaceuticals (Austedo), Supernus Pharmaceuticals (Myobloc), Rohto Pharmaceutical (UDI-001), and several others are investigating their candidates for Cerebral Palsy management in the 7MM.

Cerebral Palsy Market Analysis 

Cerebral Palsy Market to increase due to the Stem cell therapy, which is a novel treatment for cerebral palsy compared with symptomatic standard care that has shown a significant positive effect on gross motor function. Also, increasingly compelling evidence that cerebral palsy can have a genetic component, studies are testing interventions such as deep brain stimulation (DBS) and personalized medicine for the treatment of Cerebral Palsy patients. However, the growth of the Cerebral Palsy Market will be hampered due to the limited availability of animal models for functional studies. Also, the issues of concern for children with cerebral palsy are wide-ranging, chronic, difficult to quantify, resistant to change, and more reflective of disability than illness. These parameters lead to frustration for the clinician who evaluates the status of a child with cerebral palsy. And there is a high unmet need for the current therapies for the treatment of Cerebral Palsy. 

Scope of the Cerebral Palsy Market Insight Report  

• Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
• Study Period: 3-year historical (2018-2020) and 10-year forecasted analysis (2021-2030).
• Cerebral Palsy Markets Segmentation: By Geographies and By Cerebral Palsy Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Cerebral Palsy Companies investigating its drug candidates: Ipsen, Abbvie, Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and several others. 
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Cerebral Palsy Therapeutics Market

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Cerebral Palsy Diagnostics Market Report

View Other Reports

• Spastic Cerebral Palsy- Market

DelveInsight's Spastic Cerebral Palsy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Cerebral Palsy - Epidemiology Forecast

DelveInsight's Cerebral Palsy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cerebral Palsy.

• Spastic Cerebral Palsy - Epidemiology Forecast

DelveInsight's Spastic Cerebral Palsy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Spastic Cerebral Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Spastic Cerebral Palsy - Pipeline

Spastic Cerebral Palsy Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Spastic Cerebral Palsy market. 

Browse Blog Posts

• Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics

The key players operating in the segment of Migraine Neuromodulation Devices comprise Theranica Bio-Electronics LTD, electroCore, Inc., Cirrus Healthcare Products, Cefaly Technology, eNeura Inc., Prolivio, Neuros Medical, Neurolief Ltd., tVNS Technologies GmbH, Medtronic, WAT Medical, Chordate Medical, Chordate Medical, Soterix mEDICAL among others.

• Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle

Currently, companies such as Athersys, Abbvie, Bristol-Myers Squibb, Lumosa Therapeutics, Teijin Pharma Limited, etc. are involved in developing therapies for Acute Ischemic Stroke (AIS).

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:

Shruti Thakur
info@delveinsight.com   
+1(919)321-6187

www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg